|Bid||83.04 x 2200|
|Ask||83.18 x 900|
|Day's Range||80.36 - 83.32|
|52 Week Range||41.07 - 83.61|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 28, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.17|
LivaNova today announced it received U.S. FDA 510(k) clearance for B-Capta, the new in-line, blood-gas monitoring system integrated into the S5 HLM.
LivaNova announced it has randomized 300 patients in the ANTHEM HFrEF pivotal study, which was FDA approved under the Breakthrough Devices Program.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 887 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]